… However, the efficacy of … retrospective analysis of AEs and drug efficacy in patients with
NSCLC whose EGFR mutation status had been confirmed and who all received 250 mg gefitinib …

… Gefitinib (TKI) has shown the effectiveness in patients with advanced NSCLC. This
retrospective study is to analyze the EGFR mutation rate and the efficacy of TKI on the NSCLC …

… shows more clinical efficacy in cases with leptomeningeal carcinomatosis than gefitinib19,20…
the comparative efficacy of gefitinib, erlotinib, and afatinib, we retrospectively evaluated the …

… the response and survival benefit of gefitinib administration. We have retrospectively reviewed
data of all patients who received a single regimen of gefitinib in our institution from August …

… retrospectively analyzed the efficacy of the 2 nd EGFR-TKI administration after failure of the
initial gefitinib … who had previously achieved disease control with gefitinib. The risks of the 2 …

… 2.8 tablets of 250 mg gefitinib (150 mg erlotinib is equal to 600–700 mg gefitinib).13, … gefitinib
and erlotinib treatment. In this study, we retrospectively evaluated the difference in efficacy …

… retrospectively analyzed consecutive patients with advanced NSCLC who were diagnosed
before October 2010, treated with gefitinib … patients who respond to gefitinib. The secondary …

… To address this important gap, we undertook a retrospective study to assess the efficacy
of adjuvant gefitinib versus adjuvant chemotherapy (AC) in patients with completely resected …

… This retrospective analysis is in keeping with recent trial findings that the use of an EGFRTKI
in the second line appears to be equivalent to docetaxel in patients with advanced NSCLC …

… time from the date of gefitinib administration was 10.6 months … predictors for tumor response
to gefitinib. The response rate of the … This retrospective analysis suggests that gefitinib was of …